Hypertension and nephrology

[Lercanidipine in hypertension]


OCTOBER 20, 2016

Hypertension and nephrology - 2016;20(05)

[Lercanidipine is a third generation DHP type calcium antagonist. It’s antihypertensive efficacy is proven using in monotherapy or combined treatment as well. The main advantage compared with the first and second generation DHP calcium antagonists is that fewer side effects, especially the much less common ankle oedema. Renal protective effect has proven by experimental and clinical studies, but in the future more prospective randomized studies should be supported this benefit. The drug is very useful for diabetes, obesity associated with hypertension due to the metabolic „neutrality”. The key of successful antihypertensive is the high level persistence. From this point of view the lercanidipine is a very useful factor during the treatment.]



Further articles in this publication

Hypertension and nephrology

[Letter to the Reader]

A szerkesztôség

Hypertension and nephrology

[State Ceremony on the 150th Anniversary of the Birth of Sándor Korányi ]

RADÓ János

Hypertension and nephrology

[A new perspective on the extrarenal regulation of sodium and water balance]

AGÓCS Róbert István, SUGÁR Dániel, SULYOK Endre, SZABÓ J. Attila

[The regulation of the homeostasis of sodium and water is one of the oldest fields in medical research. Our article exhibits a new aspect of sodium balance: the concept of the regulated sodium storage taking place in the interstitium of the skin. We summarize the history of the research carried out in this area, beginning with the discovery of osmotically inactive sodium reservoirs to the localization of these buffers and the elucidation of the role of a regulating cutaneous cascade, which has an effect on blood pressure. Glycosaminoglycan (GAG) macromolecules present in the skin interstitium, come into reversible contact with the excess of dietary sodium intake. Thus in addition to the known role of the kidney, the above system may contribute to the regulation of sodium- and water balance and thereby to the regulation of blood pressure.]

Hypertension and nephrology

[Quality of Life: How Health is Considered. A European Comparison ]


Hypertension and nephrology

[The Great Fat Bluff]


All articles in the issue

Related contents

Lege Artis Medicinae

[Cardiovascular risk factors and risk assessment]


[The author summarises the most important cardiovascular risk factors. Concerning public health, the three most important synergistic factors are smoking, hypertension and abnormal cholesterol. Abnormal total lipid profile, visceral obesity, elevated glucose and uric acid levels and hypertonia all contribute to the global cardiometabolic risk. A number of studies and metaanalyses have confirmed the correlations of the risk factors and cardiovascular events (organ damage, clinical events, mortality). The concomitant occurance of risk factors increases the rate of risk. Risk estimation methods have been designed on the basis of proven correlations and they have been continuously improved and made more reliable owing to the assessment of more and more factors.]

Hypertension and nephrology

[Angiotensin-converting enyzme inhibitors before and after myocardial infarction]


[In this review current knowledge related to the coronary atherosclerosis and angiotensin-enzym inhibitor is discussed. The earlier recognition to the effect of ACE inhibitors and ARBs to slow or reverse left ventricular remodelling is well known and accepted but the effect of these drugs on the atherosclerotic process itself may be aqual important. The focus should be now how to treat the early phase of coronary atherosclerosis, how to treat safety the hypertensive patient in the setting of coronary stenosis, how to treat the acute myocardial infarction’s patient with renal failure, and at least how to improve the long-time adherence in the primer and secunder prevention too.]

Hypertension and nephrology

[The CONADPER-HU program. Objective and methodology of the program. Patients. Basaline data]

KISS István, ALFÖLDI Sándor, BARNA István, JÁRAI Zoltán, SIMONYI Gábor, SZEGEDI János, PAKSY András, UGRAI Péter, KÉKES Ede

[The aim of the study was to increase the rate of target blood pressure and reduce blood pressure variability. This dual objective ensures optimal therapeutic success. In order to reach this goal, we wanted to increase the care of patients with hypertension by increasing patient-physician-assistant cooperation and providing telemedicinal devices.]

Lege Artis Medicinae


CSIKY Botond

[According to national and international guidelines, thiazide diuretics are considered first-line antihypertensive agents. They lower blood pressure and cardiovascular risk efficiently without serious side effects in low-dose monotherapy or in combination with other antihypertensives. Furthermore, when given in combination with certain antihypertensive agents, a synergistic effect develops. Indapamide is a thiazide-like diuretic, virtually without metabolic side effects. Diuretics may have special benefit in the elderly and in certain target organ damage or concomittant disease (heart failure, hypervolaemia, etc). Adequate use of diuretic therapy can prevent hypertensive end-organ damage and other complications, and improves the patients' quality of life.]

Hypertension and nephrology

[Hypertension and left ventricular hypertrophy]


[Left ventricular hypertrophy (LVH) is defined as an increase in the mass of the left ventricle. In addition to the absolute increase in mass, the geometric pattern of LVH also may be important. LVH can be secondary to an increase in wall thickness, an increase in cavity size, or both. LVH as a consequence of hypertension usually presents with an increase in wall thickness. This increase in mass predominantly results from a chronic increase in afterload of LV caused by the hypertension, although there is also a genetic component. A significant increase in the number and/or size of sarcomeres is the main pathologic mechanism, but hypertension may also result in interstitial fibrosis. The estimation of mass is commonly derived from measurements obtained by echocardiography. LVH is associated with increased incidence of systolic and/or diastolic dysfunction, heart failure, myocardial infarction, ventricular arrhythmias, sudden cardiac death, aortic root dilatation, and a cerebrovascular event. The cardiovascular risk is directly related to the degree of mass. The regression of LVH is associated with a reduction in cardiovascular risk and improved cardiac function. Regression of LVH is associated with weight loss, dietary sodium restriction, and use of ACE inhibitors, ARBs, some calcium channel blockers, and some sympatholytic agents.]